The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC).
Ashwin Gollerkeri
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Michael S. Gordon
Research Funding - Pfizer
John M. Burke
Consultant or Advisory Role - Dendreon; Genomic Health; Seattle Genetics; Spectrum Pharmaceuticals
Ralph Hauke
No relevant relationships to disclose
Jiri Tomasek
Honoraria - seminar presentation
Donald A. Richards
No relevant relationships to disclose
Christopher DiSimone
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Scott S. Tykodi
Research Funding - Pfizer
Amit R. Mehta
No relevant relationships to disclose
Charles Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Rachelle Perea
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Nicholas J. Vogelzang
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Honoraria - GlaxoSmithKline; Novartis; Pfizer